The AIM-listed company’s ProBiotix and Italy’s Nutrilinea carried out a three-month study of 40 patients by the Center of Diabetes and Metabolic Diseases at the University of Pavia and Fondazione IRCCS Policlinico San Matteo in Italy.
Statistically significant reductions were shown in both systolic and diastolic blood pressure levels as well as cholesterol levels, which was consistent with a UK study in 2017.
ProBiotix and Nutrilinea agreed on the study last May, with the Italian company funding the development, manufacture and human studies for a new blood pressure product in return for 12 months exclusivity for the European market, which began on 18 December.
ProBiotix retains exclusivity for the UK and all markets outside Europe.
“Because hypertension effects millions of people globally and is a serious risk factor for cardiovascular disease, we are excited to offer a natural product that has been clinically proven to lower hypertension,” said ProBiotix chief executive Steve Prescott.
“Adding this new formulation to our portfolio of existing products that target cholesterol reduction, CholBiome and CholBiome x3, allows ProBiotix to offer a best in class cardiovascular health solutions to consumers.”